source
- Replimune to file third FDA application for RP1 cancer therapy after productive talksReplimune announced it will submit a third marketing application for its experimental cancer therapy RP1, following what the company described as productive discussions with the Food and Drug Admin…
- AstraZeneca explores options after anselamimab fails Phase 3, while Imfinzi and Tremfya receive label expansionsAstraZeneca announced that its experimental monoclonal antibody anselamimab failed to meet the primary endpoint in two Phase 3 trials for a specific patient group. The company said it will explore…